VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
QTRX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
QTRXQuanterix Corporation
$2.90$137M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
QTRX logo

Quanterix Corporation

QTRX
NASDAQ · Life Science Tools
$2.90
At close - Nov 6, 4:00 PM EST - USD
Market Cap$137M
P/E-1.1x
52W High$8.77
Volume474.77K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Quanterix Revenue Rebounds Amid Deepening Operating Losses

Quanterix's revenue recovered to $32.9M in 2026Q2, up 34.6% year over year, but the business remains deeply unprofitable, with operating margin at -150.2% and a net loss of $48.9M that suggests losses may be structural rather than cyclical.

GrowthMixed
ProfitabilityWeak
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

QTRX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-103% Peers

P/E is 103% below peer median

03

Market leadership

RS 35 · Lag

Laggard (Underperforming 65% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystConfirmed earnings · Nov 9

Market performance

Price History →

Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
QTRX-54.98%
S&P 500 (^GSPC)+7.63%
1-Year Return
QTRX-41.98%
S&P 500 (^GSPC)+9.69%
3-Year Return
QTRX-86.88%
S&P 500 (^GSPC)+72.20%
5-Year Return
QTRX-94.97%
S&P 500 (^GSPC)+60.58%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$139M+2.4% YoY
Net income FY25
-$107M-178.1% YoY
Free cash flow FY25
-$80M-107.2% YoY
Operating margin FY25
-79.2%-40.4 pts YoY
ROIC (FY25)-26.8%
Avg ROIC 5Y-51.3%
ROE (TTM)-43.6%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (42%)
Revenue Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 10, 2026
-$1.04-153.5%
vs -$0.41
$33M-12.2%
vs $37M
Q2 2026
May 6, 2026
-$0.39-25.8%
vs -$0.31
$36M-1.2%
vs $37M
Q2 2026
Mar 2, 2026
-$0.38-40.7%
vs -$0.27
$44M+14.8%
vs $38M
Q4 2025
Nov 10, 2025
-$0.73-217.4%
vs -$0.23
$40M+6.8%
vs $38M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Defense World·4d ago
Head-To-Head Comparison: Quantum-Si (NASDAQ:QSI) vs. Quanterix (NASDAQ:QTRX)

Quantum-Si (NASDAQ: QSI - Get Free Report) and Quanterix (NASDAQ: QTRX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends. Valuation and Earnings This table compares Quantum-Si and Quanterix"s

Business Wire·Oct 28, 2026
Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, November 9, 2026, at 8:30 AM ET, to discuss its third quarter 2026 financial results. Quanterix will issue a press release regarding its third quarter 2026 financial results prior to the conference call on Monday, November 9, 2026. The press release will be posted on the Quanterix website at http://www.quanterix.c.

GuruFocus·Oct 7, 2026
Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals

Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a leading i

Business Wire·Sep 25, 2026
Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today reported significant progress on the Content Innovation Engine it introduced at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting new updates at the European Society for Spatial Biology (ESSB) September 28-October 1, 2026. This progress underscores Quanterix's growing leadership in spatial biology content, delivering the assays researchers need to do more pivotal work. Built on the.

Filtered for Quanterix CorporationMore Headlines
04

Compare before deciding

Benchmark QTRX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Quanterix Corporation (QTRX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
QTRX logoQTRXQuanterix CorporationCurrent
$2.90$136.61M-1.112.38%-80.29%-43.59%—
SEER logoSEERSeer, Inc.
$1.63$89.62M-1.3215.57%-490.71%-27.23%—
CDNA logoCDNACareDx, Inc
$78.56$4.06B33.5813.79%25.86%34.08%—
NTRA logoNTRANatera, Inc.
$310.67$44.49B-271.7335.9%-5.66%-9.18%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$277.62$7.74B-23.85-100%—-34.15%—
BIO logoBIOBio-Rad Laboratories, Inc.
$381.57$10.27B10.050.65%39.45%14.07%—

Compare QTRX vs Peers

Quanterix Corporation (QTRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SEER

Most directly comparable listed peer for QTRX.

Scale Benchmark

vs TMO

Larger-name benchmark to compare QTRX against a more recognizable public peer.

Peer Set

Compare Top 5

vs SEER, CDNA, NTRA, PRAX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

QTRX SEC Filings & Documents

Quanterix Corporation (QTRX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 10, 2026·SEC

Material company update

Jun 10, 2026·SEC

Material company update

Jun 9, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 2, 2026·SEC

FY 2025

Mar 17, 2025·SEC

10-Q Quarterly Reports

5
FY 2026

Aug 10, 2026·SEC

FY 2026

May 6, 2026·SEC

FY 2025

Nov 10, 2025·SEC

Get notified when QTRX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

QTRX Frequently Asked Questions

Quanterix Corporation (QTRX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Quanterix Corporation's revenue?

Quanterix Corporation (QTRX) reported $153.3M in revenue over the trailing twelve months. Revenue was $138.7M in fiscal year 2025. That is 1038% more than the $12.2M of fiscal year 2015.

How fast is Quanterix Corporation growing?

Quanterix Corporation (QTRX) grew revenue by 23.4% over the trailing twelve months, compared with the twelve months before.

Is QTRX profitable?

No. Quanterix Corporation (QTRX) reported a net loss of $123.1M over the trailing twelve months.

Dividend & Returns
What is QTRX's return on equity?

Quanterix Corporation (QTRX) had a return on equity (ROE) of -43.6% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Quanterix Corporation's free cash flow?

Quanterix Corporation (QTRX) had negative free cash flow of $74.0M over the trailing twelve months.

What if you invested $1,000 in QTRX back in 2015?

Total return calculator · dividends reinvested · 11+ years of data

See returns →